Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Dexcom, Inc. (NASDAQ: DXCM) celebrates the expansion of coverage for its continuous glucose monitoring system under the Non-Insured Health Benefits (NIHB) program in Canada. This decision allows all insulin-dependent diabetes clients to access the Dexcom G6 system, significantly improving diabetes management for First Nations and Inuit peoples. Previously announced changes in coverage criteria now ensure a higher degree of accessibility to critical healthcare technology. Leading medical professionals advocate this technology's benefits for managing diabetes effectively. The Dexcom G6 provides real-time glucose data and alerts, facilitating better diabetes care and potentially reducing long-term complications. Dexcom's commitment to improving health outcomes is further emphasized by comparisons to similar expansions in U.S. coverage by CMS.
Dexcom (NASDAQ: DXCM) announces the expansion of Medicare coverage for its continuous glucose monitoring (CGM) system, the Dexcom G7, to include all insulin users and certain non-insulin users. This change grants approximately 1.5 million additional Medicare patients in the U.S. access to the most accurate CGM available without extra costs compared to other brands. The MOBILE study provided critical clinical evidence demonstrating significant improvements in A1C levels and time in range for users. Dexcom emphasizes the affordability and ease of use of its products, as the Dexcom G7 has a MARD of 8.2% and is set up easily. The updated policy is regarded as the most significant single expansion of CGM coverage to date, potentially improving the quality of life for millions of diabetes patients.
DexCom, Inc. (NASDAQ:DXCM) will announce its first quarter 2023 financial results on April 27, 2023, after market close. Management will host a conference call at 4:30 p.m. ET to discuss performance, which will also be available via webcast on the investors.dexcom.com site. Participants can listen by dialing (888) 414-4585 for US/Canada or (646) 960-0331 for international calls, using the confirmation ID "9430114". As a leader in diabetes care, DexCom focuses on empowering users through continuous glucose monitoring (CGM) systems, enhancing diabetes management globally.